



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/534,091

05/06/2005

Juha-Matti Savola

TUR-168

2654

32954 7590 08/15/2008

JAMES C. LYDON
100 DAINGERFIELD ROAD
SUITE 100
ALEXANDRIA, VA 22314

EXAMINER

GEMBEH, SHIRLEY V

ART UNIT

PAPER NUMBER

1618

MAIL DATE

DELIVERY MODE

08/15/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Interview Summary	Application No. 10/534,091	Applicant(s) SAVOLA ET AL.	
	Examiner SHIRLEY V. GEMBEH	Art Unit 1618	

All participants (applicant, applicant's representative, PTO personnel):

(1) SHIRLEY V. GEMBEH. (3)_____.

(2) James Lydon. (4)_____.

Date of Interview: 08 August 2008.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☒ Personal [copy given to: 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No.

If Yes, brief description: _____.

Claim(s) discussed: 23.

Identification of prior art discussed: _____.

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Applicant sent in proposed amendment specifying the administration via oromucosal route. Discussed how the instant invention differs from the prior art in that the via mucosal route allows absorption in the mucosal system versus the absorption in the liver. Applicant also discussed that the invention would not have been obvious to one of ordinary skill in the art to administer a large dose since larger doses have been known to cause cardiac arrest.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

/Shirley V. Gembah/ 8/8/08

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required